Grace Therapeutics, Inc.: Form 10-Q for the period ended Dec 31, 2024
Filed with the SEC on Feb 13, 2025 and accepted by EDGAR at Feb 13, 2025, 07:30 ET.
Sections
The sections of this filing are being extracted from EDGAR and appear here in about a minute. Meanwhile, read the original on sec.gov. The main document on sec.gov.
Figures reported in this filing
Standardized line items from the XBRL in this filing, for the period ended 2024-12-31. Comparative periods it repeats are left out.
| Line item | Period | Value | XBRL concept |
|---|---|---|---|
| Research and development | 3 months2024-10-01 to 2024-12-31 | $2.2m | us-gaap:ResearchAndDevelopmentExpense |
| Research and development | 9 months2024-04-01 to 2024-12-31 | $7.9m | us-gaap:ResearchAndDevelopmentExpense |
| Operating income | 3 months2024-10-01 to 2024-12-31 | −$3.7m | us-gaap:OperatingIncomeLoss |
| Operating income | 9 months2024-04-01 to 2024-12-31 | −$13.5m | us-gaap:OperatingIncomeLoss |
| Income tax | 3 months2024-10-01 to 2024-12-31 | −$605.0k | us-gaap:IncomeTaxExpenseBenefit |
| Income tax | 9 months2024-04-01 to 2024-12-31 | −$2.2m | us-gaap:IncomeTaxExpenseBenefit |
| Net income | 3 months2024-10-01 to 2024-12-31 | −$4.2m | us-gaap:NetIncomeLoss |
| Net income | 9 months2024-04-01 to 2024-12-31 | −$10.2m | us-gaap:NetIncomeLoss |
| Diluted EPS | 3 months2024-10-01 to 2024-12-31 | −$0.36 | us-gaap:EarningsPerShareDiluted |
| Diluted EPS | 9 months2024-04-01 to 2024-12-31 | −$0.89 | us-gaap:EarningsPerShareDiluted |
| Basic EPS | 3 months2024-10-01 to 2024-12-31 | −$0.36 | us-gaap:EarningsPerShareBasic |
| Basic EPS | 9 months2024-04-01 to 2024-12-31 | −$0.89 | us-gaap:EarningsPerShareBasic |
| Diluted shares (weighted) | 3 months2024-10-01 to 2024-12-31 | 11,506,234 shares | us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding |
| Diluted shares (weighted) | 9 months2024-04-01 to 2024-12-31 | 11,506,234 shares | us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding |
| Operating cash flow | 9 months2024-04-01 to 2024-12-31 | −$11.9m | us-gaap:NetCashProvidedByUsedInOperatingActivities |
| Cash and equivalents | At period end2024-12-31 | $11.1m | us-gaap:CashAndCashEquivalentsAtCarryingValue |
| Current assets | At period end2024-12-31 | $11.9m | us-gaap:AssetsCurrent |
| Total assets | At period end2024-12-31 | $61.2m | us-gaap:Assets |
| Current liabilities | At period end2024-12-31 | $2.0m | us-gaap:LiabilitiesCurrent |
| Total liabilities | At period end2024-12-31 | $9.1m | us-gaap:Liabilities |
| Shareholders' equity | At period end2024-12-31 | $52.1m | us-gaap:StockholdersEquity |
Source: SEC EDGAR, the filing index for accession 0001140361-25-004153. Last ingested by Listed: Nov 6, 2026, 02:04 ET. Listed shows no prices and gives no investment advice.